Idxg stock.
IDXG Stock Return DVA Stock Return ... We favor stocks that offer meaningfully greater expected return in the next 3 years; These returns are calculated based on our revenue forecast and Price to Sales Ratio (P/S) scenarios considered; Similar Price To Sales Ratio (P/S) scenarios are considered for both stocks and each scenario is weighted ...
Get the latest Interpace Biosciences, Inc. (IDXG) stock news and headlines to help you in your trading and investing decisions.Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.Interpace Announces Coverage of ThyraMIR® with UnitedHealthcare PR Newswire PARSIPPANY, N.J., April 18, 2017 PARSIPPANY, N.J. , April 18, 2017 /PRNewswire/ --Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of $0.10.Revenue of $9.8M (-5.6% Y/Y). ... @Lydie Agreed, surprised the stock did not pop more on news of sale of the pharma business ...Interpace Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | OTC Markets: IDXG | OTC Markets
IDXG is important to the diagnostics industry. The company has been transformed. Seeking Alpha - Go to Homepage. Trending. My Portfolio. My Authors. Top Stocks. Latest News. Markets. Stock Ideas.6,321 $49,999. Insider Actions. Interpace Biosciences Inc. company facts, information and financial ratios from MarketWatch.
Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.
Interpace Biosciences Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time IDXG stock price.IDXG Stock Profile. The stock’s lowest price of the day was 1.02 on January 7, 2023, an increase of 11.11 percent from the start of the trading day. Interpace Biosciences has an extremely high probability of encountering financial difficulties soon. Investors have also seen negative returns in the last 90 days.IDXG stock fares better after Case 1, with a 39.2% chance of rise over the next month (21 trading days) under Case 1 (where the stock has suffered a 5% loss over the previous month), versus, a 34.9% chance of rise for Case 2. This would suggest that it is better to buy IDXG stock after a recent dropAug 17, 2020 · Interpace Biosciences Inc (IDXG) stock is down -31.64% while the S&P 500 is up 0.35% as of 2:31 PM on Monday, Aug 17. IDXG is down -$1.83 from the previous closing price of $5.78 on volume of 968,030 shares. Over the past year the S&P 500 has risen 15.77% while IDXG is down -47.33%. IDXG lost -$8.53 per share the over the last 12 months. Interpace Biosciences, Inc. (IDXG Stock Report) Oncocyte Corporation (OCX Stock Report) Novan, Inc. (NOVN Stock Report) Heading into the remainder of the month, there is already a slew of other biotech penny stocks gaining attention. Will these find their way onto your list before the end of October 2020? Biotech Penny Stocks To Watch …
When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...
PARSIPPANY, NJ, March 04, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or “the Company”) announced today that the Pittsburgh business Times has designated Interpace Diagnostics as its 2018 Top Life Sciences Company award winner.This recognition is granted to those businesses in the region that provide services to the …
Aug 9, 2023 · IDXG Stock Message Board for Investors. Interpace Diagnostics Group, Inc. Stock Price, News and Company Updates. Message Board Total Posts: 33 PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR ® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet established medical criteria for the …Discover historical prices for IDXG stock on Yahoo Finance. View daily, weekly or monthly format back to when Interpace Biosciences, Inc. stock was issued.MiMedx Group (MDXG, $7.57) RSI Indicator left the overbought zone on November 22, 2023. Track Mimedx Group Inc (MDXG) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors. The estimated Net Worth of Thomas W. Burnell is at least $437 Mille dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $11,723 and over the last 2 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres e CEO & Director at Interpace Biosciences Inc.Find the latest iBX Group, Inc. (IBXG) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 28, 2023 · EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding. Zacks News for IDXG TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue ...
Ticker: IDXG CIK: 1054102 Form Type: 10-K Annual Report Accession Number: 0001493152-23-009106 Submitted to the SEC: Mon Mar 27 2023 4:38:59 PM EST Accepted by the SEC: Mon Mar 27 2023 Period: Saturday, December 31, 2022 Industry: Surgical And Medical Instruments And Apparatus External Resources: Stock Quote Social Media SEC.gov Bookmark the ...James has made over 1 trades of the Interpace Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of IDXG stock worth $5,750 on 29 July 2020. The largest trade James's ever made was exercising 5,000 units of Interpace Biosciences Inc stock on 29 July 2020 worth over $5,750.Sep 30, 2023 · PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue was $9.1 million, a $0.9 million increase over third quarter 2022. Interpace Biosciences Inc (OTC:IDXG) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...EPS forecast (this quarter) $0.11. Annual revenue (last year) $31.8M. Annual profit (last year) -$22.0M. Net profit margin. -18.42%.
Interpace Announces Coverage of ThyraMIR® with UnitedHealthcare PR Newswire PARSIPPANY, N.J., April 18, 2017 PARSIPPANY, N.J. , April 18, 2017 /PRNewswire/ --
The estimated Net Worth of Thomas W. Burnell is at least $438 mil dollars as of 21 May 2021. Dr Burnell owns over 10,855 units of Interpace Biosciences Inc stock worth over $12,917 and over the last 3 years he sold IDXG stock worth over $0. In addition, he makes $425,004 as Pres y CEO & Director at Interpace Biosciences Inc.Dr D IDXG stock SEC Form 4 insiders trading. Dr has made over 1 trades of the Interpace Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,855 units of IDXG stock worth $94,221 on 21 May 2021.10,855 units of IDXG stock worth $94,221 on 21 May 2021.Pre-Open Stock Movers 05/17: Buffett's New Buys Gain, Home Depot Up on Earnings ... (IDXG) (HMNY) (ATHX) Higher; (HDSN) (CUDA) (MNKD) Lower (more...) Jul 19 ...After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data ... Interpace Biosciences Inc. 1.05. Delayed Data. As of Nov 21. -0.09 / -7.89%. Today’s Change. 0.51. Today ||| 52-Week Range. 3.54. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Step 1: Set up a spreadsheet to track your trades. You can do this with your program of choice, such as Excel, or by hand. Make columns for: Purchase date. Amount invested. Number of shares ...© Valve Corporation. Tous droits réservés. Toutes les marques commerciales sont la propriété de leurs titulaires aux États-Unis et dans d'autres pays.Aug 31, 2022 · Interpace Biosciences on Wednesday said it had closed the sale of its pharma services business to Flagship Biosciences.IDXG CEO Thomas Burnell said with the completion of the deal, the company's ...
EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding. Zacks News for IDXG TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue ...
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies. RNAscope ® in situ hybridization (ISH) is a new Interpace offering that …
A list of the latest Interpace Biosciences Inc News - IDXG Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.Jul 25, 2023 · See the latest Interpace Biosciences Inc stock price (PINX:IDXG), related news, valuation, dividends and more to help you make your investing decisions. Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT ® test, representing an increase of approximately $2,400 per assay over previous …Interpace Biosciences Inc’s trailing 12-month revenue is $37.4 million with a -40.8% profit margin. Year-over-year quarterly sales growth most recently was -28.1%. There are not analysts providing consensus earnings estimates for the current fiscal year. Interpace Biosciences Inc does not currently pay a dividend.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.IDXG Stock Profile. The stock’s lowest price of the day was 1.02 on January 7, 2023, an increase of 11.11 percent from the start of the trading day. Interpace Biosciences has an extremely high probability of encountering financial difficulties soon. Investors have also seen negative returns in the last 90 days.Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts.While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of …PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the terms of the Rights Offering, the Company is distributing non-transferable subscription …Interpace Diagnostics Announces Pricing of Public Offering to Raise $3.6 Million PR Newswire PARSIPPANY, N.J., Feb. 3, 2017 PARSIPPANY, N.J. , Feb. 3, 2017
60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Interpace Diagnostics Announces European Patent Approval For Underlying Technology of its ThyraMIR® microRNA Classifier PR Newswire PARSIPPANY, N.J., April 3,See the company profile for Interpace Biosciences, Inc. (IDXG) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...Instagram:https://instagram. best crypto brokerageschd calculatorurbn inchow to get started on forex Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts.While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of … currency trading brokersgtrx stock Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. cigna dental savings plan dentists Third quarter Net Revenue was. Find the latest Interpace Diagnostics Group, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading …LONG BEACH, Calif., November 13, 2023--The Beauty Health Company announced financial results for the third quarter ended September 30, 2023. Find the latest The Beauty Health Company (SKIN) stock ...Interpace Diagnostics to Present New Data on Thyroid Product Performance Four Posters Accepted on ThyGenX® and ThyraMIR® to be Presented at USCAP PR Newswire